Selected References:
- Allergan, Inc. 2025. Vraylar Product Label. National Institute of Health DailyMed Database. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm.
- Balamurali S, et al. 2026. Cariprazine in Human Milk: Cautionary Implications for Use During Lactation. J Clin Psychopharmacol; doi: 10.1097/JCP.0000000000002174. Epub ahead of print.
- Culpepper L, et al. 2022. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatr Dis Treat; 18: 995-1011.
- Herold R, et al. 2024. Cariprazine maintenance treatment during pregnancy – a case report. Front Psychiatry; 15:1421395.
- Huybrechts K, et al. 2023. Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. JAMA Psychiatry: 80(2):156–166.
- U.S. FDA. 2015. Vraylar (Cariprazine) pharmacology review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000PharmR.pdf. Accessed May 23, 2024.
